These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 7851055)

  • 21. [Theoretical research for therapy of infection].
    Shimizu K
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):815-23. PubMed ID: 1655924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo postantibiotic effect in a thigh infection in neutropenic mice.
    Vogelman B; Gudmundsson S; Turnidge J; Leggett J; Craig WA
    J Infect Dis; 1988 Feb; 157(2):287-98. PubMed ID: 3121761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time.
    Hanberger H
    Scand J Infect Dis Suppl; 1992; 81():1-52. PubMed ID: 1322561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacodynamics of aminoglycosides.
    Lacy MK; Nicolau DP; Nightingale CH; Quintiliani R
    Clin Infect Dis; 1998 Jul; 27(1):23-7. PubMed ID: 9675444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postantibiotic effect of a combination of antimicrobial agents on pseudomonas aeruginosa.
    Sood P; Mandal A; Mishra B
    Chemotherapy; 2000; 46(3):173-6. PubMed ID: 10765031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
    Zhu ZY; Li RC
    J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Aminoglycosides and polymyxins].
    Molina J; Cordero E; Palomino J; Pachón J
    Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):178-88. PubMed ID: 19303668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance.
    Burgess DS
    Chest; 1999 Mar; 115(3 Suppl):19S-23S. PubMed ID: 10084455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of fluoroquinolones.
    Lode H; Borner K; Koeppe P
    Clin Infect Dis; 1998 Jul; 27(1):33-9. PubMed ID: 9675446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminoglycoside therapy in infectious diseases.
    Poulikakos P; Falagas ME
    Expert Opin Pharmacother; 2013 Aug; 14(12):1585-97. PubMed ID: 23746121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.
    Dudley MN
    Am J Med; 1991 Dec; 91(6A):45S-50S. PubMed ID: 1767806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
    Yadav R; Landersdorfer CB; Nation RL; Boyce JD; Bulitta JB
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.
    Craig WA
    J Antimicrob Chemother; 1993 May; 31 Suppl D():149-58. PubMed ID: 8335516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.
    McCormack JP; Schentag JJ
    Drug Intell Clin Pharm; 1987 Feb; 21(2):187-92. PubMed ID: 3829911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.
    Novelli A; Mazzei T; Fallani S; Cassetta MI; Conti S
    J Chemother; 1995 Aug; 7(4):355-62. PubMed ID: 8568546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-a-day cephalosporins: reality or myth?
    Scaglione F; Dugnani S; Fraschini F
    J Chemother; 1995 May; 7 Suppl 1():13-5. PubMed ID: 8618107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies of dosing regimens and combination effects of aminoglycosides and beta-lactam in an experimental Pseudomonas aeruginosa infection in mice].
    Kikuchi K
    Kansenshogaku Zasshi; 1991 Feb; 65(2):216-25. PubMed ID: 2066605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.